SEC Comment Letter for Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) (CRBP) — Jan 11, 2018
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)
Date: Jan. 11, 2018 · CIK: 0001595097 · Accession: 0000000000-18-001202
AI Filing Summary & Sentiment
Reasoning
Letter
January 11, 2018 Yuval Cohen Chief Executive Officer Corbus Pharmaceuticals Holdings, Inc. 100 River Ridge Drive Norwood, MA 02062 Corbus Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed January 5, 2018 File No. 333-222447Re: Dear Mr. Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Steven Skolnick
Show Raw Text
January 11, 2018
Yuval Cohen
Chief Executive Officer
Corbus Pharmaceuticals Holdings, Inc.
100 River Ridge Drive
Norwood, MA 02062
Corbus Pharmaceuticals Holdings, Inc.
Registration Statement on Form S-3
Filed January 5, 2018
File No. 333-222447Re:
Dear Mr. Cohen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Steven Skolnick